142 related articles for article (PubMed ID: 17875349)
1. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.
Fournillier A; Gerossier E; Evlashev A; Schmitt D; Simon B; Chatel L; Martin P; Silvestre N; Balloul JM; Barry R; Inchauspé G
Vaccine; 2007 Oct; 25(42):7339-53. PubMed ID: 17875349
[TBL] [Abstract][Full Text] [Related]
2. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.
Martin P; Parroche P; Chatel L; Barretto C; Beck A; Trépo C; Bain C; Lone YC; Inchauspé G; Fournillier A
J Med Virol; 2004 Nov; 74(3):397-405. PubMed ID: 15368525
[TBL] [Abstract][Full Text] [Related]
3. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
4. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
[TBL] [Abstract][Full Text] [Related]
5. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins.
Engler OB; Schwendener RA; Dai WJ; Wölk B; Pichler W; Moradpour D; Brunner T; Cerny A
Vaccine; 2004 Nov; 23(1):58-68. PubMed ID: 15519708
[TBL] [Abstract][Full Text] [Related]
6. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
[TBL] [Abstract][Full Text] [Related]
7. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
[TBL] [Abstract][Full Text] [Related]
8. Polyfunctional CD8(+) T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope.
Tan AC; Eriksson EM; Kedzierska K; Deliyannis G; Valkenburg SA; Zeng W; Jackson DC
Antiviral Res; 2012 May; 94(2):168-78. PubMed ID: 22504097
[TBL] [Abstract][Full Text] [Related]
9. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
[TBL] [Abstract][Full Text] [Related]
10. Novel peptide-based vaccines efficiently prime murine "help"-independent CD8+ T cell responses in the liver.
Dikopoulos N; Riedl P; Schirmbeck R; Reimann J
Hepatology; 2004 Aug; 40(2):300-9. PubMed ID: 15368434
[TBL] [Abstract][Full Text] [Related]
11. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
[TBL] [Abstract][Full Text] [Related]
12. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins.
Abraham JD; Himoudi N; Kien F; Berland JL; Codran A; Bartosch B; Baumert T; Paranhos-Baccala G; Schuster C; Inchauspé G; Kieny MP
Vaccine; 2004 Sep; 22(29-30):3917-28. PubMed ID: 15364440
[TBL] [Abstract][Full Text] [Related]
14. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.
Folgori A; Capone S; Ruggeri L; Meola A; Sporeno E; Ercole BB; Pezzanera M; Tafi R; Arcuri M; Fattori E; Lahm A; Luzzago A; Vitelli A; Colloca S; Cortese R; Nicosia A
Nat Med; 2006 Feb; 12(2):190-7. PubMed ID: 16462801
[TBL] [Abstract][Full Text] [Related]
15. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes.
Fattori E; Zampaglione I; Arcuri M; Meola A; Ercole BB; Cirillo A; Folgori A; Bett A; Cappelletti M; Sporeno E; Cortese R; Nicosia A; Colloca S
Gene Ther; 2006 Jul; 13(14):1088-96. PubMed ID: 16554842
[TBL] [Abstract][Full Text] [Related]
16. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
[TBL] [Abstract][Full Text] [Related]
17. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.
Gómez CE; Perdiguero B; Cepeda MV; Mingorance L; García-Arriaza J; Vandermeeren A; Sorzano CÓ; Esteban M
J Virol; 2013 Jul; 87(13):7282-300. PubMed ID: 23596307
[TBL] [Abstract][Full Text] [Related]
18. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
[TBL] [Abstract][Full Text] [Related]
20. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
